Advances in automated cell washing and concentration

Anqi Li; Gina D Kusuma; Dawn Driscoll; Nathan Smith; Dominic M Wall; Bruce L Levine; David James; Rebecca Lim

doi:10.1016/j.jcyt.2021.04.003

Advances in automated cell washing and concentration

Cytotherapy. 2021 Sep;23(9):774-786. doi: 10.1016/j.jcyt.2021.04.003. Epub 2021 May 27.

Authors

Anqi Li¹, Gina D Kusuma¹, Dawn Driscoll², Nathan Smith², Dominic M Wall³, Bruce L Levine⁴, David James⁵, Rebecca Lim⁶

Affiliations

¹ The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia; Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia.
² Cell Therapies Pty Ltd, Melbourne, Australia.
³ Cell Therapies Pty Ltd, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
⁴ Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁵ Scinogy Pty Ltd, Melbourne, Australia.
⁶ The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia; Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia. Electronic address: rebecca.lim@monash.edu.

PMID: 34052112
DOI: 10.1016/j.jcyt.2021.04.003

Abstract

The successful commercialization of cell therapies requires thorough planning and consideration of product quality, cost and scale of the manufacturing process. The implementation of automation can be central to a robust and reproducible manufacturing process at industrialized scales. There have been a number of wash-and-concentrate devices developed for cell manufacturing. These technologies have arisen from transfusion medicine, hematopoietic stem cell and biologics manufacturing where operating mechanisms are distinct from manual centrifugation. This review describes the historical origin and fundamental technologies underlying each currently available wash-and-concentrate device as well as their relative advantages and disadvantages in cell therapy applications. Understanding the specific attributes and limitations of these technologies is essential to optimizing cell therapy manufacturing.

Keywords: automation; bioprocessing; cell manufacturing; cell therapies; devices; stem cells.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Automation
Cell- and Tissue-Based Therapy*
Centrifugation
Hematopoietic Stem Cells*